Intensive Care Medicine

, Volume 36, Issue 12, pp 2060–2065

Rescue treatment for noninvasive ventilation failure due to interface intolerance with remifentanil analgosedation: a pilot study

Authors

    • Department of Anesthesiology and Intensive CareUniversity of Rome “La Sapienza”
  • Giorgio Conti
    • Department of Anesthesiology and Intensive CareCatholic University of Rome
  • Elisa Alessandri
    • Department of Anesthesiology and Intensive CareUniversity of Rome “La Sapienza”
  • Andrea Morelli
    • Department of Anesthesiology and Intensive CareUniversity of Rome “La Sapienza”
  • Gustavo Spadetta
    • Department of Anesthesiology and Intensive CareUniversity of Rome “La Sapienza”
  • Amalia Laderchi
    • Department of Anesthesiology and Intensive CareUniversity of Rome “La Sapienza”
  • Carmela Di Santo
    • Department of Anesthesiology and Intensive CareUniversity of Rome “La Sapienza”
  • Samanta Francavilla
    • Department of Anesthesiology and Intensive CareUniversity of Rome “La Sapienza”
  • Paolo Pietropaoli
    • Department of Anesthesiology and Intensive CareUniversity of Rome “La Sapienza”
Original

DOI: 10.1007/s00134-010-2026-y

Cite this article as:
Rocco, M., Conti, G., Alessandri, E. et al. Intensive Care Med (2010) 36: 2060. doi:10.1007/s00134-010-2026-y

Abstract

Purpose

To assess the feasibility of remifentanil-based sedation in hypoxemic acute respiratory failure (HARF) patients refusing to continue noninvasive ventilation (NPPV) for intolerance to two different interfaces—helmet and total face mask.

Design and setting

Prospective uncontrolled clinical investigation in a 14-bed ICU of an university hospital in Italy.

Patients

Thirty-six patients with persistent severe HARF who complained of discomfort and asked for interruption of NPPV session.

Intervention

Patients started sedation with remifentanil (0.025 μg kg−1 min−1) and the infusion rate was increased by 0.01 μg kg−1 min−1 every minute to a maximum of 0.12 μg kg−1 min−1 to obtain patient comfort.

Measurements and results

Twenty-two out of 36 patients (61%) with median (IQR) SAPS II score of 32 (30, 38) continued the NPPV treatment after the introduction of remifentanil infusion. In this success group, median (IQR) respiratory rate decreased from 34 (31, 37) to 24 (20, 26) min−1 (p < 0.0001) and PaO2/FiO2 ratio increased from 156 (144, 176) to 270 (210, 300) mmHg (p < 0.0001) after 1 h of NPPV with remifentanil-analgosedation either with helmet or total face mask. Fourteen patients failed to continue the noninvasive treatment and were intubated after a mean of 2.5 ± 2.3 h; they showed a respiratory rate decrease from 35 (30, 38) to 27 (25, 35) min−1 (p = 0.02) and an inability to increase the PaO2/FiO2 ratio above 180 mmHg. The ICU mortality in the failure group patients was 50 versus 14% in the NPPV success group (p < 0.05). The mean remifentanil dose administered was 0.07 ± 0.03 μg kg−1 min−1.

Conclusion

This clinical study suggests that a remifentanil-based sedation protocol can decrease the rate of failure in patients with intolerance to NPPV.

Keywords

Noninvasive ventilationHypoxemic acute respiratory failureMechanical ventilationRemifentanilCritical careNPPV intolerance

Copyright information

© Copyright jointly held by Springer and ESICM 2010